Charles River Laboratories (CRL) Tops Q3 EPS by 53c
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $288.50 -1.65%
Revenue Growth %: -4.3%
Financial Fact:
Interest expense: -7.08M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.3%
Financial Fact:
Interest expense: -7.08M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.33, $0.53 better than the analyst estimate of $1.80. Revenue for the quarter came in at $743.3 million versus the consensus estimate of $716.36 million.
GUIDANCE:
Charles River Laboratories sees FY2020 EPS of $7.75-$7.85, versus the consensus of $7.26.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- John Wiley & Sons, Inc. (WLYB) Misses Q1 EPS by 2c ; Offers Guidance
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
